Celadon Pharmaceuticals (CEL) Share Price, News & Analysis

Company Overview

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com

Key Stats

• Today's Range: 2.76 to 8
• 50-Day Range: 3 to 25
• 52-Week Range: 2.21 to 122.50
• Volume: 775,934 shs
• Average Volume: 281,761 shs
• Market Capitalization: £3.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CEL Stock Analysis - Frequently Asked Questions

How have CEL shares performed this year?

Celadon Pharmaceuticals' stock was trading at GBX 14 at the beginning of 2025. Since then, CEL stock has decreased by 56.4% and is now trading at GBX 6.10.
View the best growth stocks for 2025 here.

How do I buy shares of Celadon Pharmaceuticals?

Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Celadon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Avino Silver & Gold Mines (ASM).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Communication
• Current Symbol: LON:CEL
• CIK: N/A
• Web: www.celadonpharma.co.uk
• Phone: 44 20 3150 0252
• Fax: N/A
• Employees: 2,780
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (7.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,965,636.99
• Net Margins: -4,024.62%
• Pretax Margin: N/A
• Return on Equity: -187.26%
• Return on Assets: -34.40%

Debt

• Debt-to-Equity Ratio: 196.67
• Current Ratio: 1.92
• Quick Ratio: 6.97

Sales & Book Value

• Annual Sales: £123,381.65
• Price / Sales: 17.00
• Cash Flow: GBX 1.12 per share
• Price / Cash Flow: 3.05
• Book Value: GBX 3.80 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 61,329,971
• Free Float: N/A
• Market Cap: £2.10 million
• Optionable: Not Optionable
• Beta: -0.26